Literature DB >> 22016448

Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Thomas J Richards1, Naftali Kaminski, Fred Baribaud, Susan Flavin, Carrie Brodmerkel, Daniel Horowitz, Katherine Li, Jiin Choi, Louis J Vuga, Kathleen O Lindell, Melinda Klesen, Yingze Zhang, Kevin F Gibson.   

Abstract

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology with a variable and unpredictable course.
OBJECTIVES: The aim of this study was to identify and validate plasma proteins that are predictive of outcome in IPF.
METHODS: Plasma samples were available for 241 patients with IPF (140 derivation and 101 validation). In the derivation cohort, concentrations of 92 proteins were analyzed using a multiplex bead-based immunoassay and concentrations of matrix metalloproteinase (MMP)-7, MMP-1, and surfactant protein D were assessed by ELISA. In the validation cohort concentrations of intercellular adhesion molecule (ICAM)-1, IL-8, and vascular cell adhesion molecule (VCAM)-1 were assessed by bead-based multiplex assay, and S100A12 and MMP-7 by ELISA. Associations of biomarkers with mortality, transplant-free survival, and disease progression were tested in the derivation and validation cohorts using nonparametric methods of survival analysis and the Cox proportional hazards model, and an integrated risk prediction score was derived and tested.
MEASUREMENTS AND MAIN RESULTS: High concentrations of MMP-7, ICAM-1, IL-8, VCAM-1, and S100A12 predicted poor overall survival, poor transplant-free survival, and poor progression-free survival in the derivation cohort. In the independent validation cohort high concentrations of all five were predictive of poor transplant-free survival; MMP-7, ICAM-1, and IL-8 of overall survival; and ICAM-1 of poor progression-free survival. The personal clinical and molecular mortality prediction index derived in the derivation cohort was highly predictive of mortality in the validation cohort.
CONCLUSIONS: Our results suggest that plasma proteins should be evaluated as a tool for prognosis determination in prioritization of patients for lung transplantation and stratification in drug studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22016448      PMCID: PMC3262037          DOI: 10.1164/rccm.201101-0058OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  61 in total

1.  ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.

Authors:  M Demedts; U Costabel
Journal:  Eur Respir J       Date:  2002-05       Impact factor: 16.671

2.  Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury.

Authors:  Qinglang Li; Pyong Woo Park; Carole L Wilson; William C Parks
Journal:  Cell       Date:  2002-11-27       Impact factor: 41.582

Review 3.  CXC chemokines in vascular remodeling related to pulmonary fibrosis.

Authors:  Robert M Strieter; John A Belperio; Michael P Keane
Journal:  Am J Respir Cell Mol Biol       Date:  2003-09       Impact factor: 6.914

4.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans.

Authors:  Fengrong Zuo; Naftali Kaminski; Elsie Eugui; John Allard; Zohar Yakhini; Amir Ben-Dor; Lance Lollini; David Morris; Yong Kim; Barbara DeLustro; Dean Sheppard; Annie Pardo; Moises Selman; Renu A Heller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

5.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.

Authors:  Marco Chilosi; Venerino Poletti; Alberto Zamò; Maurizio Lestani; Licia Montagna; Paola Piccoli; Serena Pedron; Manuela Bertaso; Aldo Scarpa; Bruno Murer; Alessandra Cancellieri; Roberta Maestro; Gianpietro Semenzato; Claudio Doglioni
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

6.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

Authors:  Athol U Wells; Sujal R Desai; Michael B Rubens; Nicole S L Goh; Derek Cramer; Andrew G Nicholson; Thomas V Colby; Roland M du Bois; David M Hansell
Journal:  Am J Respir Crit Care Med       Date:  2003-04-01       Impact factor: 21.405

7.  Pulmonary irradiation-induced expression of VCAM-I and ICAM-I is decreased by manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy.

Authors:  Michael W Epperly; Christine A Sikora; Stacy J DeFilippi; Joan E Gretton; Dafna Bar-Sagi; Herbert Archer; Timothy Carlos; HongLiang Guo; Joel S Greenberger
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

8.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

9.  Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.

Authors:  T E King; M I Schwarz; K Brown; J A Tooze; T V Colby; J A Waldron; A Flint; W Thurlbeck; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

10.  Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium.

Authors:  John K McGuire; Qinglang Li; William C Parks
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

View more
  151 in total

1.  SLC34A2 gene mutation may explain comorbidity of pulmonary alveolar microlithiasis and aortic valve sclerosis.

Authors:  Åsa Lina M Jönsson; Ole Hilberg; Elisabeth M Bendstrup; Susie Mogensen; Ulf Simonsen
Journal:  Am J Respir Crit Care Med       Date:  2012-02-15       Impact factor: 21.405

2.  Plasma proteins for risk prediction in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-06-15       Impact factor: 21.405

Review 3.  Genomic medicine and lung diseases.

Authors:  David M Center; David A Schwartz; Julian Solway; Dorothy Gail; Aaron D Laposky; Qing S Lin; Weiniu Gan
Journal:  Am J Respir Crit Care Med       Date:  2012-05-31       Impact factor: 21.405

4.  Idiopathic pulmonary fibrosis: time to get personal?

Authors:  Imre Noth; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2013-12-15       Impact factor: 21.405

Review 5.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 6.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

7.  VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis.

Authors:  Marianna Agassandian; John R Tedrow; John Sembrat; Daniel J Kass; Yingze Zhang; Elena A Goncharova; Naftali Kaminski; Rama K Mallampalli; Louis J Vuga
Journal:  Cell Signal       Date:  2015-09-18       Impact factor: 4.315

8.  Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Claire F McGroder; Carrie P Aaron; Suzette J Bielinski; Steven M Kawut; Russell P Tracy; Ganesh Raghu; R Graham Barr; David J Lederer; Anna J Podolanczuk
Journal:  Eur Respir J       Date:  2019-09-30       Impact factor: 16.671

Review 9.  Biomarkers in idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Naftali Kaminski
Journal:  Curr Opin Pulm Med       Date:  2012-09       Impact factor: 3.155

10.  Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.

Authors:  Subramaniam Pennathur; Anuradha Vivekanandan-Giri; Morgan L Locy; Tejaswini Kulkarni; Degui Zhi; Lixia Zeng; Jaeman Byun; Joao A de Andrade; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.